Braeburn Pharma raises $110 million for opioid addiction treatment

Braeburn Pharmaceuticals, a Princeton, N.J.-based developer of treatments for opioid addiction, has raised $110 million in new funding led by Wellington Management.

Why it matters: Because Braeburn recently received FDA priority review for its lead candidate, which would become the market's first long-acting implant drug to help combat what has become a national epidemic.

• Go deeper: The impact of opioids on U.S. life expectancy